Michael W. Meshad

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç et al. · The Lancet Oncology · 2019 · 385 citations · Full text

Medicine, Hematology, Pharmacotherapy +11

A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)

Lori J. Goldstein, Mauro Mansutti, Christelle Lévy et al. · Breast Cancer Research and Treatment · 2021 · 101 citations · Full text

Medicine, Oncology, Pharmacology +16

Treatment of advanced squamous cell carcinoma of the head and neck with cisplatin, bleomycin, and methotrexate (PBM).

Ervin Tj, R. Weichselbaum, Daniel Miller et al. · PubMed · 1981 · 72 citations

Medicine, Oncology, Radiation Oncology +14

Efficacy of Oral Ondansetron, A Selective Antagonist of 5-HT3 Receptors, in the Treatment of Nausea and Vomiting Associated with Cyclophosphamide-Based Chemotherapies

Luigi X. Cubeddu, Kelly Pendergrass, Thomas Ryan et al. · American Journal of Clinical Oncology · 1994 · 42 citations

Medicine, Pharmacology, Pharmacotherapy +16

Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP)

Nicholas C. Turner, Cristina Saura, Philippe Aftimos et al. · Journal of Clinical Oncology · 2024 · 32 citations · Full text

Medicine, Oncology, Pharmacology +17